Cholesterol Testing Services Market Size to Exceed USD 37.32 Bn by 2032

The Cholesterol Testing Services Market, estimated at USD 21.64 Bn in 2025, is expected to exhibit a CAGR of 8.1% and reach USD 37.32 Bn by 2032.

The market growth is driven by rising demand for accurate and early disease detection, supported by advances in molecular diagnostics, imaging, and point-of-care testing. Growing focus on personalized medicine, supportive healthcare policies, and ongoing R&D investments are creating new opportunities for industry players.

Cholesterol testing helps determine the levels of Low Density Lipoprotein (LDL) and High Density Lipoprotein (HDL) cholesterol in the blood. High LDL cholesterol levels indicate potential cardiovascular issues while high HDL cholesterol levels are considered healthy. Cholesterol testing is performed to evaluate cardiovascular health risks and monitor cholesterol-lowering treatment effectiveness.

Global Cholesterol Testing Market- Drivers

Rising obesity rates globally is driving demand for cholesterol testing, according to World Obesity Federation Organization, estimates for global levels of overweight and obesity (BMI ≥25kg/m²), also referred to as high BMI throughout this Atlas, suggest that over 4 billion people may be affected by 2035, compared with over 2.6 billion in 2025. This reflects an increase from 38% of the world’s population in 2025 to over 50% by 2035. The rising prevalence of obesity is expected to be steepest among children and adolescents, rising from 10% to 20% of the world’s boys during the period 2025 to 2035

 Global Cholesterol Testing Market - Restraints

Financial associated with testing, constraining market growth is the costs associated with cholesterol testing. While basic tests are affordable, more accurate advanced screening options involving advanced equipment and reagents come at a higher price. This poses affordability issues, especially in developing nations with large underinsured populations. The out-of-pocket expenses deter some individuals from getting tested regularly as advised. Market players must work on developing low-cost testing solutions to improve accessibility in resource-constrained settings. Providing discounts, insurance coverage, and community healthcare programs can help expand the reachable market.

Global Cholesterol Testing Market- Opportunities

the launch and expansion of public health screening campaigns by various governments. Several countries are undertaking initiatives to enhance preventive healthcare and encourage citizens to undergo routine health checkups. For instance, the U.S. Preventive Services Task Force recommends screening all adults aged 20 and older for high cholesterol. Similarly, the UK's NHS promotes cholesterol checks for those over 40 years. These mass screening drives are helping to normalize testing and educate more people on managing cholesterol levels. As public health authorities continue investing in such awareness and testing programs, it will raise market demand. Early detection enabled by widespread screening aids in curbing healthcare expenditure related to untreated high cholesterol in the long run.

Global Cholesterol Testing Market Segmentation:

The global Cholesterol Testing Market report is segmented into service type, age group & service provider and region

Based on the service type, the market is segmented into Total Cholesterol Test, LDL Cholesterol Test, HDL Cholesterol Test,Triglyceride Test & Others. Out of which, the Total Cholesterol Test segment is expected to hold a dominant position in the global Cholesterol Testing Market during the forecast period, and this is attributed to the increasing product launch, for instance, in March, 2025, Regeneron Pharmaceuticals, Inc., U.S. based biotechnology company, announced the U.S. Food and Drug Administration (FDA) approval of Evkeeza (evinacumab-dgnb) as an adjunct to other lipid-lowering therapies

Based on the service provider, the market is segmented into staffing gaps, seasonal demand, emergencies, temporary project support, crisis response teams, telemedicine and remote care, and others (healthcare it management, etc.). Out of which, the emergencies segment is expected to hold a dominant position in the global Cholesterol Testing Market during the forecast period, and this is attributed to the increasing demand of healthcare staffing during periods of high demand, such as flu season or a global health crisis like the COVID-19 pandemic, temporary staff can help maintain patient care levels by providing additional support to cope with the increased patient load

Based on end user, the market is segmented into hospitals, nursing home and others (ambulatory centers, etc.) Out of which, the hospitals segment is expected to dominate the market over the forecast period, and this is attributed to large number of hospitals hiring skilled professionals as per the regulations. The implementation of patient centric regulations is driving the number of healthcare staffing in hospitals

Browse 35 Market Data Tables and 32 Figures spread through 180 Pages and in-depth TOC on Global Cholesterol Testing Market, By Service Type (Total Cholesterol Test, LDL Cholesterol Test, HDL Cholesterol Test, Triglyceride Test & Others) By Age Group (Geriatric, Adults & Paediatric), By Service Provider (Diagnostic Centres, Hospitals, Ambulatory Care Centers & Others) and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa).

Key Developments:

• On August, 2025, Amgen Inc., U.S. based Biopharmaceutical company, announced the collaboration with American Heart Association, sponsored an event ‘The Lower Your LDL Cholesterol Now initiative’ in U.S. in this event survey was conducted which showed more than half (51%) of Americans who have had a heart attack or stroke don't prioritize lowering LDL or "bad" cholesterol despite the increased risk
• On November 2025, Johnson & Johnson, global pharmaceutical and medical technology corporation, and announced the acquisition of Abiomed, a world leader in breakthrough heart, lung and kidney support technologies .The transaction broadens Johnson & Johnson MedTech’s (JJMT) position as a growing cardiovascular innovator, advancing the standard of care in one of healthcare’s largest unmet need disease states
• In December 2025, Clinical Reference Laboratory, a U.S.-based privately-held clinical testing laboratory in the U.S., announced the acquisition of Confirm BioSciences, a provider of comprehensive screening tools and solutions. This acquisition will expand Confirm Biosciences's access to lab testing services and R&D capabilities.

Link: https://www.coherentmarketinsights.com/market-insight/cholesterol-testing-services-market-1376

Key Takeaways of the Global Cholesterol Testing Market:

• The global Cholesterol Testing Market is expected to exhibit a CAGR of 8.1% during the forecast period.
• Among region, North America is expected to be the dominant region in the global Cholesterol Testing Market due to increasing investments in healthcare staffing by key market players. For instance, according to National Center for Chronic Disease Prevention and Health, around 86 million U.S. adults age 20 or older have total cholesterol levels above 200 mg/dL. Nearly 25 million adults in the United States have total cholesterol levels above 240 mg/dL.
• Major players operating in the global Cholesterol Testing Market include Quest Diagnostics Incorporated, Spectra Laboratories Inc., Bio-Reference Laboratories Inc., Eurofins Scientific (Luxembourg), Clinical Reference Laboratory, Inc. (CRL), ACM Medical Laboratory, Adicon Clinical Laboratory, Unilabs, SYNLAB International GmbH, and Laboratory Corporation of America Holdings (LabCorp), Bioscientia, CML Healthcare, and LloydsPharmacy